Treatment
Semaglutide clinical trials
We’re tracking 144 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT07171723RecruitingPhase 1/Phase 2
Study of LEAP2 on eating control during semaglutide treatment
This study looks at how a natural hormone called LEAP2 affects your appetite and eating behavior while you are taking semaglutide (a weight loss medicine). The results might help doctors understand how to make weight loss treatments even better.
HellerupAges 18–65 - NCT07187830Recruiting
Semaglutide for belly fat and liver health in kidney disease
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
Edmonton, AlbertaAges 18 years+ - NCT07213466RecruitingPhase 4
Personalized weight-loss medication for bipolar disorder
This study wants to see if a personalized approach with FDA-approved weight-loss medications can help people with bipolar disorder who are overweight or have obesity, while staying on their mood stabilizer treatment. It might be a good fit if you have bipolar disorder and struggle with your weight.
Rochester, MinnesotaAges 18–65 - NCT07221214RecruitingPhase 2
Testing a diabetes drug for drinking and heart health in HIV
This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.
Nashville, TennesseeAges 18–89 - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT07254572RecruitingPhase 4
Comparing diabetes drugs for heart health in prediabetes
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
WarsawAges 18–80 - NCT07295223RecruitingPhase 3
GLP-1 and SGLT2 drugs for heart attack recovery
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
León, GuanajuatoAges 18 years+ - NCT07297589RecruitingPhase 3
CT scan of heart fat after heart attack
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
León, GuanajuatoAges 18 years+ - NCT07314684RecruitingPhase 4
Semaglutide's effect on inflammation in type 2 diabetes
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
Caserta, CasertaAges 18–85 - NCT07446998RecruitingPhase 2
Study on enobosarm for weight loss in older adults on semaglutide
This trial tests if adding enobosarm (a muscle-preserving drug) to semaglutide (a weight-loss medication) can help older adults maintain muscle and improve physical function while losing weight. It may be an option for people who are already taking semaglutide and want to prevent muscle loss.
Phoenix, ArizonaAges 65–100 - NCT07677995Enrolling by invitation
Fatty acids and type 2 diabetes study
This study looks at how free fatty acids affect people with type 2 diabetes or pre-diabetes. You may be able to join if you are overweight, have high blood sugar, and are not on certain diabetes medications.
Coleraine, County LondonderryAges 18 years+ - NCT07374328RecruitingPhase 1/Phase 2
Three diabetes medicines for new type 2 diabetes
This trial tests a combination of three diabetes medicines to see if they can quickly get high blood sugar under control in people newly diagnosed with type 2 diabetes. It's designed for those whose HbA1c is 9.0% or higher.
Guangzhou, GuangdongAges 18–65 - NCT07415954RecruitingPhase 2
Testing a new diabetes medicine for blood sugar control
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
Lancaster, CaliforniaAges 18–75 - NCT06396416RecruitingPhase 4
Obesity management after kidney transplant
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
London, OntarioAges 18 years+ - NCT07589322Recruiting
How GLP-1 drugs reshape fat and metabolism
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
TaipeiAges 20–65 - NCT07597018RecruitingPhase 1
Comparing Blood Levels of Cagrilintide Versions in Adults With Overweight
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
BerlinAges 18–64 - NCT07633639Recruiting
GLP-1 Medicine After Weight-Loss Surgery in Chinese Patients
This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.
BeijingAges 18–60 - NCT07456774Enrolling by invitation
How long do people stay on Ozempic for diabetes (China study)
This study looks at how well people in China stick with taking Ozempic (a once-weekly injection) compared to other diabetes medicines. It helps researchers understand if this medicine is easier to keep taking long-term.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07280221Enrolling by invitation
Wegovy real-world weight loss study in Korea
This study tracks how well Wegovy (a once-weekly injection for weight loss) works for people in Korea who are just starting the medication. It helps doctors understand real-world results outside of a research clinic.
DaejeonAges 19 years+ - NCT07154238Enrolling by invitation
Semaglutide for weight management: a real-world study
This study looks at the experiences of people using injectable semaglutide for weight loss, as well as the doctors who prescribe it. It aims to understand how the treatment works in everyday life.
Bad OeynhausenAges 18 years+ - NCT07057310Enrolling by invitationPhase 4
Weight Loss Drug for Postmenopausal Women With Obesity
This study tests a GLP-1 agonist medication (like Ozempic) to help postmenopausal women lose weight and improve physical and blood vessel health. It focuses on women aged 46–60 with obesity.
Jacksonville, FloridaAges 46–60 - NCT07055607Enrolling by invitation
Real-world study of Wegovy for weight management
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
BarcelonaAges 18 years+ - NCT06959784Enrolling by invitationPhase 4
A study on new diabetes drugs for heart health and remission
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
BeijingAges 30–70 - NCT06954090Enrolling by invitationPhase 4
Urine test to guide early treatment in type 2 diabetes
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Herlev, Hajdú-BiharAges 18 years+
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 144 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.